[1] R A S,M W S,W T O,et al.Intraocular sarcoid-like reaction in patients with chronic lymphocytic leukemia[J].Canadian journal of ophthalmology.Journal canadien d'ophtalmologie,2023,11(2):86-93. [2] Suarez S M D M,Roldan M A,Payer A C,et al.Treatment of chronic lymphocytic leukemia in the personalized medicine Era[J].Pharmaceutics,2023,16(1):451-453. [3] Ureshino H,Kamachi K,Kimura S.Second treatment-free remission attempt in patients with chronic myeloid leukemia[J].Clinical lymphoma,myeloma & leukemia,2023,24(4):138-141. [4] Yuying Liu,Zeyu Yang,Qingqing Zhang,et al.Recent advances in signaling pathways and kinase inhibitors for leukemia chemotherapy[J].Curr Med Chem,2024,16(1):295-298. [5] Mert T,Rashad I,Olgu C E,et al.Nilotinib-associated multiple silent arterial stenosis in a patient with chronic myeloid leukemia[J].Turkish journal of haematology :official journal of Turkish Society of Haematology,2023,13(3):221-223. [6] Yi J T,YongHao Y,Choon M T,et al.Mortality trends of chronic lymphocytic leukaemia in the united states with the emergence of targeted therapy[J].British journal of haematology,2023,204(3):1114-1117. [7] Yong Huang,Chunyan Yuan,Qiwei Liu,Lingying Wang.KIF23 promotes autophagy-induced imatinib resistance in chronic myeloid leukaemia through activating Wnt/β-catenin pathway.Clin Exp Pharmacol Physiol[J].2022,49(12):1334-1341. [8] Darici S,Alkhaldi H,Horne G,Jorgensen H.G,Marmiroli S,Huang X.Targeting PI3K/Akt/mTOR in AML:rationale and clinical evidence[J].Clin Med,2020,9(9):2934. [9] Penuela R,Hernandez I,Pineda F M,et al.Spontaneous remission without treatment of acute myelomonocytic leukemia associated with COVID-19 infection[J].Hematology,transfusion and cell therapy,2023,13(10):512-513. [10] Shinichi M,Shuichi O,Yuko M,et al.Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma[J].International journal of hematology,2023,119(2):156-163. [11] Simge E,Meliha N.Successful management of Ibrutinib-induced thrombocytopenia in a patient with chronic lymphocytic leukemia:no interruption only reduction[J].Turkish journal of haematology :official journal of Turkish Society of Haematology,2023,23(3):54-59. [12] Giovanni P D,Roberta L,Riccardo B,et al.COVID-19 vaccination:Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients[J].Hematological oncology,2022,41(3):559-562. [13] Esma B,Lejla M,Una G,et al.Curcumin decreases viability and inhibits proliferation of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cell lines[J].Metabolites,2022,13(1):58. [14] Ji-Hea Kim,Ka-Won Kang,Yong Park,Byung Soo Kim.CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26)[J].Heliyon,2023,9(11):22091. [15] Wenjin L,Peng F,Gan F,et al.Application of modified Matutes score containing CD200 in diagnosis of chronic lymphocytic leukemia[J].Zhong nan da xue xue bao.Yi xue ban = Journal of Central South University.Medical sciences,2022,47(12):1689-1694. [16] Braun TP,Eide C A,Druker B J.Response and resistance to BCR-ABL1-targeted therapies[J].Cancer Cell,2020,37(4):530-542. [17] Fabris L,Juracek J,Calin G.Non-coding RNAs as cancer hallmarks in chronic lymphocytic leukemia[J].Int Mol Sci,2020,21(18):6720. [18] Ostini A,Mourtada-Maarabouni M.Investigation into the role of long-non-coding RNAMIATin leukemia[J].Noncoding RNA,2023,9(4):47. [19] Li S,Jiang M,Wang L,Yu S.Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers:recent advancement[J].Biomed Pharmacother,2020,129(1):110389. [20] Meng S,Alanazi R,Ji D,et al.Role of TRPM7 kinase in cancer[J].Cell Calcium,2021,96(1):102400. [21] Birgit Hoeger,Wiebke Nadolni,Sarah Hampe,et al.Inactivation of TRPM7 kinase targets AKT signaling and cyclooxygenase-2 expression in human CML cells[J].Function,2023,4(6):53. [22] Clark R E,Apperley J F,Copland M,Cicconi S.Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression[J].Blood Adv,2021,5(4):1102-1109.
2024, Vol. 30 
冀公网安备13080202000677号